Diseases, Conditions, Syndromes

Favorable outcomes seen in long term for ALLR3 trial

(HealthDay)—For children with B-cell precursor acute lymphoblastic leukemia with late bone marrow relapse, risk stratification by minimal residual disease seems to be an effective strategy for treatment, according to a ...

Oncology & Cancer

Blincyto approval expanded for specific leukemia

(HealthDay)—The U.S. Food and Drug Administration says it has expanded approval for Blincyto (blinatumomab) to include adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but who ...

Oncology & Cancer

Molecular minimal disease in remission predicts AML relapse

(HealthDay)—The detection of molecular minimal residual disease is associated with increased relapse rates in acute myeloid leukemia (AML), according to a study published in the March 29 issue of the New England Journal ...

Oncology & Cancer

Flow cytometry assesses minimal residual disease in myeloma

(HealthDay)—Data on methods used for assessing minimal residual disease (MRD) in multiple myeloma (MM) are presented in a report published online Oct. 23 in the International Journal of Laboratory Hematology.

Oncology & Cancer

Combo Rx plus stem-cell tx ups PFS in multiple myeloma

(HealthDay)—Combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus stem-cell transplantation is associated with longer progression-free survival than RVD alone for adults with multiple myeloma, ...

Oncology & Cancer

Study supports minimal residual disease as end point in myeloma

(HealthDay)—For patients with newly diagnosed multiple myeloma (MM), minimal residual disease (MRD)-negative status is associated with improved survival, according to a meta-analysis published online Sept. 15 in JAMA Oncology.

page 1 from 3